Financial Tear Sheet

Financial Tear Sheet

Corporate Profile

Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases. We create distinct and transformative treatments for endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following product candidates:

  • Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
  • MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause

Primary IR Contact

Connie Chang
Vice President, Corporate Affairs
Millendo Therapeutics, Inc.
Phone: 734-864-8006
E-mail: chang@millendo.com

Stock Quote

Price Change
Volume % Change  
Intraday High 52 Week High
Intraday Low 52 Week Low
Today's Open Currency US Dollar
Previous Close Exchange


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart